New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: MFA Financial, Inc (NYSE:MFA), Penn West Petroleum Ltd (USA) (NYSE:PWE), Antares Pharma Inc (NASDAQ:ATRS), Solta Medical Inc (NASDAQ:SLTM)
MFA Financial, Inc (NYSE:MFA) showed a volume of 2.18 million shares by the end of last trade whereas the average volume of the stock remained 2.79 million shares. The stock opened the session at $7.14 but then moved to $7.15. At that price, the stock showed a positive performance of 0.42%. MFA Financial, Inc., is engaged in the business of investing, on a leveraged basis, in residential Agency mortgage-backed securities (MBS) and Non-Agency MBS. Its business objective is to generate net income for distribution to its stockholders resulting from the difference between the interest and other income it earn on its investments and the interest expense it pays on the borrowings, which it uses to finance its leveraged investments and its operating costs.
Will MFA Continue To Move Higher? Find Out Here
Penn West Petroleum Ltd (USA) (NYSE:PWE) opened the session at $8.55and closed the session at $8.67. The stock showed a positive performance of 0.93% in previous trading session. Penn West Petroleum Ltd. (Penn West), formerly Penn West Energy Trust, is a Canadian exploration and production company. Penn West is engaged in the business of acquiring, exploring, developing, exploiting and holding interests in petroleum and natural gas properties and related assets. Penn West participates in the exploration for, and the development and production of, oil and natural gas principally in western Canada. The majority of the Company’s proved plus probable reserves are located in Canada in Alberta, British Columbia, Saskatchewan, Manitoba and the Northwest Territories.
For How Long PWE will fight for Profitability? Read This Trend Analysis report
Antares Pharma Inc (NASDAQ:ATRS) opened the session at $4.60 and closed the session at $4.65. The stock showed a positive performance of 1.53% in previous trading session. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva,
Why Should Investors Buy ATRS After The Recent Gain? Just Go Here and Find Out
Solta Medical Inc (NASDAQ:SLTM) the stock decreased -0.68% and finished the session at $2.91. Traded with volume of 2.16 million shares in the prior session and the average volume of the stock remained 1.92 million shares. The beta of the stock remained 2.70. Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company's systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets. The Company’s portfolio of products includes six brands that are primarily designed for aesthetic applications: The Fraxel re:pair system provides ablative laser skin resurfacing while the non-ablative Fraxel platform and Clear + Brilliant systems provide treatment for skin rejuvenation.
Will SLTM Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)